Cooper LT (2009) Myocarditis. N Engl J Med 360(15):1526–1538

Article  CAS  PubMed  PubMed Central  Google Scholar 

Caforio ALP, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB et al (2013) Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 34(33):2636–2648

Article  PubMed  Google Scholar 

Amioka N, Nakamura K, Kimura T, Ohta-Ogo K, Tanaka T, Toji T et al (2021) Pathological and clinical effects of interleukin-6 on human myocarditis. J Cardiol 78(2):157–165

Article  PubMed  Google Scholar 

Nishii M, Inomata T, Takehana H, Takeuchi I, Nakano H, Koitabashi T et al (2004) Serum levels of interleukin-10 on admission as a prognostic predictor of human fulminant myocarditis. J Am Coll Cardiol 44(6):1292–1297

Article  CAS  PubMed  Google Scholar 

Sagar S, Liu PP, Cooper LT (2012) Myocarditis. Lancet 379(9817):738–747

Article  PubMed  Google Scholar 

Maisch B (2019) Cardio-immunology of myocarditis: focus on immune mechanisms and treatment options. Front Cardiovasc Med 6:48

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rose NR (2011) Critical cytokine pathways to cardiac inflammation. J Interferon Cytokine Res 31(10):705–710

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zheng SY, Dong JZ (2022) Role of Toll-like receptors and Th responses in viral myocarditis. Front Immunol 13:843891

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yokoe I, Kobayashi H, Kobayashi Y, Giles JT, Yoneyama K, Kitamura N et al (2018) Impact of tocilizumab on N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis without cardiac symptoms. Scand J Rheumatol 47(5):364–370

Article  CAS  PubMed  Google Scholar 

Kleveland O, Kunszt G, Bratlie M, Ueland T, Broch K, Holte E et al (2016) Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial. Eur Heart J 37(30):2406–2413

Article  CAS  PubMed  Google Scholar 

Kleveland O, Ueland T, Kunszt G, Bratlie M, Yndestad A, Broch K et al (2018) Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1β in non-ST-elevation myocardial infarction. Int J Cardiol 271:1–7

Article  PubMed  Google Scholar 

Fu B, Xu X, Wei H (2020) Why tocilizumab could be an effective treatment for severe COVID-19? J Transl Med 18(1):164

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hossein Heydari A, Ghaffari S, Khani Z, Heydari S, Eskandari Z, Esmaeil HM (2023) MiR-21, and Tocilizumab interactions improve COVID-19 myocarditis outcomes. Ther Adv Cardiovasc Dis 17:17539447231182548

Article  CAS  PubMed  PubMed Central  Google Scholar 

Niño-Taravilla C, Espinosa-Vielma YP, Otaola-Arca H, Poli-Harlowe C, Tapia LI, Ortiz-Fritz P (2020) Pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 treated with tocilizumab. Pediatr Rep 12(3):142–148

Article  PubMed  PubMed Central  Google Scholar 

De Luca G, Cavalli G, Campochiaro C, Tresoldi M, Dagna L (2018) Myocarditis: an interleukin-1-mediated disease? Front Immunol 9:1335

Article  PubMed  PubMed Central  Google Scholar 

Lim BK, Choe SC, Shin JO, Ho SH, Kim JM, Yu SS et al (2002) Local expression of interleukin-1 receptor antagonist by plasmid DNA improves mortality and decreases myocardial inflammation in experimental coxsackieviral myocarditis. Circulation 105(11):1278–1281

Article  CAS  PubMed  Google Scholar 

Nakano A, Matsumori A, Kawamoto S, Tahara H, Yamato E, Sasayama S et al (2001) Cytokine gene therapy for myocarditis by in vivo electroporation. Hum Gene Ther 12(10):1289–1297

Article  CAS  PubMed  Google Scholar 

Colantuoni M, Jofra Hernandez R, Pettinato E, Basso-Ricci L, Magnani L, Andolfi G et al (2023) Constitutive IL-1RA production by modified immune cells protects against IL-1-mediated inflammatory disorders. Sci Transl Med 15(698):eade3856

Article  CAS  PubMed  Google Scholar 

Cavalli G, Pappalardo F, Mangieri A, Dinarello CA, Dagna L, Tresoldi M (2016) Treating life-threatening myocarditis by blocking interleukin-1. Crit Care Med 44(8):e751-754

Article  CAS  PubMed  Google Scholar 

Trpkov C, MacMullan P, Feuchter P, Kachra R, Heydari B, Merchant N et al (2021) Rapid response to cytokine storm inhibition using anakinra in a patient with COVID-19 myocarditis. CJC Open 3(2):210–213

Article  PubMed  Google Scholar 

Maunier L, Charbel R, Lambert V, Tissières P, CLOVIS study group (2022) Anakinra in pediatric acute fulminant myocarditis. Ann Intensive Care 12(1):80

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kaya Z, Dohmen KM, Wang Y, Schlichting J, Afanasyeva M, Leuschner F et al (2002) Cutting edge: a critical role for IL-10 in induction of nasal tolerance in experimental autoimmune myocarditis. J Immunol 168(4):1552–1556

Article  CAS  PubMed  Google Scholar 

Wang ZH, Liao YH, Yuan J, Jin XJ, Yu M, Chen RZ et al (2020) Continued elevation of plasma IL-4 and IL-17 predicts the progression from VMC to DCM. Dis Markers 2020:9385472

Article  CAS  PubMed  PubMed Central  Google Scholar 

Diny NL, Baldeviano GC, Talor MV, Barin JG, Ong S, Bedja D et al (2017) Eosinophil-derived IL-4 drives progression of myocarditis to inflammatory dilated cardiomyopathy. J Exp Med 214(4):943–957

Article  CAS  PubMed  PubMed Central  Google Scholar 

Taimeh Z, Loughran J, Birks EJ, Bolli R (2013) Vascular endothelial growth factor in heart failure. Nat Rev Cardiol 10(9):519–530

Article  CAS  PubMed  Google Scholar 

Medamana J, Clark RA, Butler J (2017) Platelet-derived growth factor in heart failure. Handb Exp Pharmacol 243:355–369

Article  CAS  PubMed  Google Scholar